

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	).	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/072,900 02/12/2002		Isabelle Amould-Reguigne	03806.0537	3572	
5487 7590 09/19/2005				EXAMINER	
	DEHLER	CEUTICALS INC.	EMCH, GREGORY S		
ROUTE 20		CEUTICALS INC.	ART UNIT	PAPER NUMBER	
MAIL CODE: D303A				1649	
BRIDGEWATER, NJ 08807				DATE MAILED: 09/19/2005	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)		
	10/072,900	ARNOULD-REGUIGNE ET AL.		
Office Action Summary	Examiner	Art Unit		
	Gregory S. Emch	1649		
The MAILING DATE of this communicate Period for Reply	on appears on the cover sheet w	ith the correspondence address		
A SHORTENED STATUTORY PERIOD FOR WHICHEVER IS LONGER, FROM THE MAIL  - Extensions of time may be available under the provisions of 37 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutor. Failure to reply within the set or extended period for reply will, I any reply received by the Office later than three months after the earned patent term adjustment. See 37 CFR 1.704(b).	ING DATE OF THIS COMMUNION CFR 1.136(a). In no event, however, may a ration.  The period will apply and will expire SIX (6) MON by statute, cause the application to become AB	CATION. reply be timely filed VTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).		
Status				
1) Responsive to communication(s) filed o	n <i>8/16/2004</i>			
	☐ This action is non-final.			
,	·			
closed in accordance with the practice u				
Disposition of Claims				
4) Claim(s) is/are pending in the ap 4a) Of the above claim(s) is/are w 5) Claim(s) is/are allowed.				
6) Claim(s) is/are rejected.				
7) Claim(s) is/are objected to.				
8) Claim(s) are subject to restriction	and/or election requirement.			
Application Papers				
9) The specification is objected to by the Ex				
10) The drawing(s) filed on is/are: a)				
Applicant may not request that any objection				
Replacement drawing sheet(s) including the				
11)☐ The oath or declaration is objected to by	the Examiner. Note the attache	d Oπice Action or form P1O-152.		
Priority under 35 U.S.C. § 119				
12) Acknowledgment is made of a claim for a) All b) Some * c) None of:  1. Certified copies of the priority doc 2. Certified copies of the priority doc 3. Copies of the certified copies of the application from the International	cuments have been received. cuments have been received in A he priority documents have been	Application No		
* See the attached detailed Office action for		received.		
A44-ahmaa4/a\				
Attachment(s)  1) Notice of References Cited (PTO-892)	4) Interview	Summary (PTO-413)		
<ul> <li>Notice of References Cited (PTO-692)</li> <li>Notice of Draftsperson's Patent Drawing Review (PTO-3)</li> <li>Information Disclosure Statement(s) (PTO-1449 or PTO Paper No(s)/Mail Date</li> </ul>	948) Paper No( 0/SB/08) 5) Notice of	(s)/Mail Date Informal Patent Application (PTO-152) O-90C. LSL [for Application of the first of the f		



# UNITED STATES DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

APPLICATION NO./ CONTROL NO.	FILING DATE	FIRST NAMED INVENTOR / PATENT IN REEXAMINATION		ATTORNEY DOCKET NO.
			EXAMINER	
			ART UNIT	PAPER
				09122005

DATE MAILED:

Please find below and/or attached an Office communication concerning this application or proceeding.

#### **Commissioner for Patents**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821(a)(1) and (a)(2). A computer readable form (CRF) of the sequence listing was submitted. However, the CRF could not be processed by the Scientific and Technical Information Center (STIC) for the reason(s) set forth on the attached CRF Diskette Problem Report.

Applicant is given ONE MONTH, or THIRTY DAYS, whichever is longer, from the mailing date of this letter within which to comply with the sequence rules, 37 CFR 1.821 - 1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a). In no case may an applicant extend the period for reply beyond the SIX MONTH statutory period. Direct the reply to the undersigned. Applicant is requested to return a copy of the attached CRF Diskette Problem Report with the reply.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Gregory S. Emch whose telephone number is (571) 272-8149. The examiner can normally be reached on Monday through Friday from 8:30AM to 5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Janet L. Andres can be reached at (571) 272-0867. The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pairdirect.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Gregory S. Emch, Ph. D. Patent Examiner

Art Unit 1649 September 12, 2005

	Application No.	Applicant(s)				
	10/072,900	ARNOULD-RFGLIGNE				
Notice to Comply	Examiner	Art Unit				
	Gregory S. Ench	1649				
NOTICE TO COMPLY WITH REQU	JIREMENTS FOR PATENT	APPLICATIONS				
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES						
Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).						
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):						
1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).						
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).						
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).						
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."						
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).						
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).						
☐ 7. Other:						
Applicant Must Provide: ☑ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".						
☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.						
A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).						
For questions regarding compliance to these requirements, please contact:						
For Rules Interpretation, call (703) 308-4216 For CRF Submission Help, call (703) 308-4212 Patentln Software Program Support Technical Assistance						
To Purchase Patentin Software	703-306-260					



# RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: /0/072,900 A
Source: //EW16
Date Processed by STIC: 8/19/04

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO-REDUCE ERRORED SEQUENCE LISTINGS; PLEASE USE THE CHECKER VERSION 4.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a> , EFS Submission User Manual cPAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box-1450, Alexandria, VA 22313-1450
- Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 06/05/04):
   U.S. Patent and Trademark Office, 220 20<sup>th</sup> Street S., Customer Window, Mail Stop Sequence, Crystal Plaza Two, Lobby, Room 1B03, Arlington, VA 22202

Revised 05/17/04 ·



IFW16

RAW SEQUENCE LISTING

DATE: 08/19/2004


PATENT APPLICATION: US/10/072,900A

TIME: 10:06:51

Input Set : A:\PTO.LM.txt

Output Set: N:\CRF4\08192004\J072900A.raw

3 <110> APPLICANT: Aventis Pharma SA ARNOULD-REGUIGNE, Isabelle PRADES, Catherine Does Not Comply 6 ROSIER-MONTUS, Marie-Francoise Corrected Diskette Needec 7 NAUDIN, Laurent 8 LEMOINE, Cendrine 9. DEAN, Michael 10 DENEFLE, Patrice 12 <120> TITLE OF INVENTION: NUCLEIC ACIDS OF THE HUMAN ABCA12 GENE, VECTORS CONTAINING SUCH NUCLEIC 13 ACIDS, AND USES THEREOF 15 <130> FILE REFERENCE: 03806.0537 C--> 17 <140> CURRENT APPLICATION NUMBER: US/10/072,900A C--> 17 <141> CURRENT FILING DATE: 2002-02-12 17 <150> PRIOR APPLICATION NUMBER: US 60/267,715 18 <151> PRIOR FILING DATE: 2001-02-12 E--> 20 <160> NUMBER OF SEQ ID NOS: 38 40 P



/0/072,900A 2

<210>40 last sequence is submitted file

<211>68
<212> DNA
<213> Artificial

<220>
<223> primer

<400> 40
ctctagaatt cggcctccgt ggccgtttaa acgctagcgc ccgggcttaa ttaagtcgac

60
tctagagc

68

MI

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

RAW SEQUENCE LISTING ERROR SUMMARY
PATENT APPLICATION: US/10/072,900A

TIME: 10:06:52

Input Set : A:\PTO.LM.txt

Output Set: N:\CRF4\08192004\J072900A.raw

## Invalid <213> Response:

Use of "Artificial" only as "<213> Organism" response is incomplete, per 1.823(b) of New Sequence Rules. Valid response is Artificial Sequence.

Seq#:7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31 Seq#:32,33,34,35,36,37,38,39,40

### VERIFICATION SUMMARY

PATENT APPLICATION: US/10/072,900A

DATE: 08/19/2004 TIME: 10:06:52

Input Set : A:\PTO.LM.txt

Output Set: N:\CRF4\08192004\J072900A.raw

```
L:17 M:270 C: Current Application Number differs, Replaced Current Application No
L:17 M:271 C: Current Filing Date differs, Replaced Current Filing Date
L:30 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1
L:318 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:8460
L:320 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:8520
L:324 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:8640
L:328 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 after pos.:8760
L:347 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:2
L\!:\!531 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:5340
L:627 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:8220
L:629 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:8280
L:633 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:8400
L:637 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 after pos.:8520
L:1222 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:5
L:1562 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:5 after pos.:1728
L:1742 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:6
L:2076 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:6 after pos.:1698
L:20 M:203 E: No. of Seq. differs, <160> Number Of Sequences:Input (38) Counted (40)
```